Last reviewed · How we verify
Mycophenolate Mofetil plus prednisolone
Mycophenolate Mofetil plus prednisolone is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh. It is currently FDA-approved. Also known as: Intervention.
At a glance
| Generic name | Mycophenolate Mofetil plus prednisolone |
|---|---|
| Also known as | Intervention |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants (PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma (PHASE2)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- Dupilumab Therapy in Nephrotic Syndrome in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate Mofetil plus prednisolone CI brief — competitive landscape report
- Mycophenolate Mofetil plus prednisolone updates RSS · CI watch RSS
- Post Graduate Institute of Medical Education and Research, Chandigarh portfolio CI
Frequently asked questions about Mycophenolate Mofetil plus prednisolone
What is Mycophenolate Mofetil plus prednisolone?
Mycophenolate Mofetil plus prednisolone is a Small molecule drug developed by Post Graduate Institute of Medical Education and Research, Chandigarh.
Who makes Mycophenolate Mofetil plus prednisolone?
Mycophenolate Mofetil plus prednisolone is developed and marketed by Post Graduate Institute of Medical Education and Research, Chandigarh (see full Post Graduate Institute of Medical Education and Research, Chandigarh pipeline at /company/post-graduate-institute-of-medical-education-and-research-chandigarh).
Is Mycophenolate Mofetil plus prednisolone also known as anything else?
Mycophenolate Mofetil plus prednisolone is also known as Intervention.
What development phase is Mycophenolate Mofetil plus prednisolone in?
Mycophenolate Mofetil plus prednisolone is FDA-approved (marketed).
Related
- Manufacturer: Post Graduate Institute of Medical Education and Research, Chandigarh — full pipeline
- Also known as: Intervention
- Compare: Mycophenolate Mofetil plus prednisolone vs similar drugs
- Pricing: Mycophenolate Mofetil plus prednisolone cost, discount & access